Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0239946 (liver fibrosis)
 8,268 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

As part of a double-blind, randomized, controlled trial to evaluate the effect of colchicine on liver cirrhosis, 43 cirrhotic patients were assigned to either a placebo (20 patients) or a colchicine (23 patients) treatment group. Colchicine 1 mg and an indistinguishable placebo were administered orally on a daily dose 5 days a week. In the colchicine group, 12 were males and 11 females, while in the control group 13 were males and 7 females. The time elapsed between diagnosis and inclusion in the study was 14.1 mo for the controls and 14.5 mo for the patients on colchicine. Mortality related to the liver disease occurred in 4 patients on colchicine and 8 patients on placebo. Although the probability of surviving in the colchicine group was greater than that of the placebo, the difference did not reach statistically significant levels. Of the colchicine-treated patients, in three a remarkable decrease in liver fibrosis was observed in serial biopsies. In two other patients, carcinoma of the liver developed. Six of the survivors on colchicine have improved clinically, noticing disappearance of ascites and edema, as well as a decrease in the size of the spleen. All the survivors on placebo continue to show clinical deterioration. In contrast to the usual drop of serum albumin seen in the cirrhotic patients, those receiving colchicine increased and maintained their serum albumin levels throughout the study. Serum proline values were elevated only in the alcohol cirrhotic patients. Serum alkaline phosphatase increased only in those patients receiving colchicine. The results indicate that in some cases, liver fibrosis could be modified by treatment with antifibrotic drugs. The use of colchicine at present should remain within controlled studies.
 ...
PMID:Treatment of cirrhosis with colchicine. A double-blind randomized trial. 37 54

Eight weeks following pinealectomy in adult male Wistar rats, zinc levels of various tissues were found to be significantly altered: zinc in thoracic aorta was significantly increased, and in serum, pituitary, adrenal, heart, lung, and body hair, it was decreased. Serum biochemical analysis indicated that there was a significant elevation of cholesterol, alkaline phosphatase, sodium, urea, and creatinine in serum from pinealectomised rats. Liver, spleen, and thymus weights were lower following pinealectomy, although hearts were increased. The effects of pinealectomy on zinc levels in serum and tissues and on serum cholesterol and alkaline phosphatase may be related to its effects on vascular reactivity and liver fibrosis.
 ...
PMID:Alteration of tissue zinc distribution and biochemical analysis of serum following pinealectomy in the rat. 54 73

Plasma activities of alkaline phosphatase, (AP), transaminases and total lactate dehydrogenase (LDH) with isoenzymes were determined in mice inhaling 50 and 550 ppm vinyl chloride (VC). The animals were also autopsied and the tissue pathology was studies. The total LDH activity was elevanted in both dose groups along with a shift to cathodic enzymes. AP was increased in animals exposed to 500 ppm and transaminases were not at all changed. Enzyme changes occurred after the appearance of tumors. Alveologenic adenomas occurred in all animals at the higher dosage and in about half of the animals inhaling the lower dose. Subperitoneal and subcutaneous hemangiosarcomas were frequent in both dose groups; but especially among 50 ppm animals. Only one animal had a hemangiosarcoma of the liver. No liver fibrosis was seen. All primary subperitoneal and subcutaneous tumors were located in fat tissue. Telangiectasis was observed in two animals in the 500 ppm series. The importance of blood vessel changes in the toxicology of vinyl chloride is discussed.
 ...
PMID:Biological effects of vinyl chloride: an experimental study. 103 93

The effects of (4R)-hexahydro-7,7-dimethyl-6-oxo-1,2,5-dithiazocine-4- carboxylic acid (SA3443), a novel cyclic disulfide compound, on the development of chronic liver injury were studied in rats, using two types of models, carbon tetrachloride (CCl4)-induced chronic liver injury and heterologous serum (swine serum)-induced liver fibrosis. SA3443 (30-100 mg/kg, p.o.) significantly suppressed increases in serum transaminase and alkaline phosphatase activity induced by CCl4-treatment for 10 weeks. This compound also inhibited increases in hepatic lipids and hydroxyproline content in CCl4-treated rats. In the histopathological studies, treatment with SA3443 resulted in a decrease in the degree of hepatic necrosis, fibrosis and steatosis. On the other hand, 8-weeks treatment with swine serum revealed hepatic fibrosis without appearance of necrosis or fatty accumulation. In this model, SA3443 (30 mg/kg, p.o.) reduced the hepatic hydroxyproline level, and diminished the formation of connective tissue in the liver. These findings indicate that SA3443 protects the liver against chronic liver injuries induced by CCl4 and heterogeneous serum.
 ...
PMID:The protective effects of SA3443, a novel cyclic disulfide, on chronic liver injuries in rats. 174 24

The present study examined the effects of (1-[(2-thiazolin-2-yl)amino]-acetyl-4-(1,3-dithiol-2-ylidene)-2,3, 4,5- tetrahydro-1H-1-benzazepin-3,5-dione hydrochloride (KF-14363) on liver fibrosis in rats with chronic liver injury induced by carbon tetrachloride (CCl4). Liver injury in male rats was induced by repeated administration of CCl4 at 0.5 ml/kg twice a week. The progression of liver fibrosis was checked in the 4th, 6th, 8th and 10th weeks using the relative amount of hepatic 4-hydroxy proline (4-hyp) to total proteine as an index of hepatic collagen. The relative amount of hepatic 4-hyp in these rats exceeded significantly that in rats not administered CCl4 by the 4th week. This progressed in proportion to the duration of CCl4 administration. In groups concurrently administered KF-14363 at 30 and 100 mg/kg/d from the 5th or 8th week of the CCl4 administration, the relative amount of hepatic 4-hyp was found to be lower in the 10th week than at the start of the KF-14363 administration. The inhibition of liver fibrosis was also observed histopathologically. The concurrently co-administration with CCl4 or KF-14363 at 30 and 100 mg/kg for 2 or 5 weeks inhibited the increases in serum transaminases and alkaline phosphatase induced by CCl4. The results show that KF-14363 inhibits liver fibrosis in a dose dependent fashion in rats with progressive liver injury.
 ...
PMID:Effects of KF-14363 on liver fibrosis in rats with chronic liver injury induced by carbon tetrachloride. 181 77

This study was initiated to investigate the long term effect of exposure to organophosphorus pesticides (O.P), with consideration to bilharziasis (an endemic parasitic disease in Egypt, usually associated with liver fibrosis). Serum levels of choline esterase (Ch E), glutamic pyruvic transaminase (SGPT), alkaline phosphatase (Alk. Ph.) and proteins were estimated among 100 (O.P.) sprayers with various duration of exposure (3 to 15 years) and among 60 controls. O.P. sprayers showed significantly higher, SGPT and Alk. Ph. and lower Ch E and serum proteins than the controls. Among sprayers, duration of exposure to O.P. was significantly correlated with their levels of Ch E, SGPT, and Alk. Ph. but not with serum proteins. Compared to other parameters, SGPT seems to be a good indicator of the hepatic effect of long term exposure to O.P. Bilharzial infection did not modify the effect of O.P. pesticides on the above mentioned parameters. Ch E of smoker sprayers was significantly less than that of non smokers. This was attributed to increased absorbtion of O.P. during smoking at work places.
 ...
PMID:Serum choline esterase and liver function among a group of organophosphorus pesticides sprayers in Egypt. 213 58

Using a monoclonal antibody to bromodeoxyuridine, we studied the cell kinetics of human hepatocellular carcinoma, liver cirrhosis, chronic active hepatitis and alcoholic liver fibrosis. Specimens were taken either by biopsy or surgery and immediately incubated with 0.1% bromodeoxyuridine solution at 37 degrees C for 45 min. After in vitro labeling, the bromodeoxyuridine taken up by the nuclei of S-phase cells was determined by the avidin-biotin-peroxidase complex method, using an anti-bromodeoxyuridine monoclonal antibody as the first antibody. The number of positive nuclei in 1,000 hepatic cells was counted, and the bromodeoxyuridine labeling index was expressed per thousand. The mean bromodeoxyuridine labeling index +/- S.D. of the cancerous portion of hepatocellular carcinoma, the noncancerous portion of hepatocellular carcinoma, liver cirrhosis, chronic active hepatitis and alcoholic liver fibrosis were 64.1 +/- 31.3, 33.6 +/- 14.4, 23.2 +/- 20.8, 9.1 +/- 6.1 and 21.6 +/- 13.0, respectively. The mean bromodeoxyuridine labeling index of the hepatocellular carcinoma cancerous portion was statistically higher than that of any other group. There was no statistical difference by the t test or the Wilcoxon test between the noncancerous portion of hepatocellular carcinoma and liver cirrhosis, and these two groups were proved interdependent by chi 2 test (Fisher's exact test), whether they were subdivided by bromodeoxyuridine labeling index greater than or equal to 10 or not. Bromodeoxyuridine labeling index was not significantly correlated with the usual biochemical parameters such as serum AST, ALT, gamma-GTP, alkaline phosphatase, lactate dehydrogenase, cholinesterase, albumin, and alpha-fetoprotein.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:S-phase cells in diseased human liver determined by an in vitro BrdU-anti-BrdU method. 284 68

A case report is presented of a 43-year-old woman with generalized peliosis hepatitis that developed during longterm use of oral contraceptives (OCs). The patient had been in good health until the last 2 years when she began to experience vague epigastric pains and a feeling of abdominal distension. Several months prior to admission, she had started to complain of itching and fatigue. There was no history of dark urine, white stools, or hepatitis. On physical examination, no jaundice or cutaneous stigmata of chronic liver disease were observed. Laboratory studies showed a normal erythrocyte sedimentation rate and hematological blood count. A radionuclide study of the liver showed hepatomegaly; especially the left lobe was enlarged. A computerized tomographic scan of the liver showed multiple areas of decreased density in both of the enlarged lobes. There was no evidence of a tumor. Selective transfemoral angiography of the celiac artery also showed hepatic enlargement but no signs of a space-occupying lesion. At laparoscopy, the liver was grossly enlarged and had a lumpy appearance, but again there were no signs of a tumor. No evidence of veno-occlusive disease or hepatocellular adenoma was found. The diagnosis was peliosis hepatitis. The OCs were withdrawn, and the patient was discharged. Regular follow-up in the outpatient department showed no decrease in the size of the liver. The alkaline phosphatase level rose. The fatigue became worse, and cholestyramine was prescribed for progressive itching. In September 1980, the patient was admitted for reevaluation. A repeated CT scan and angiography of the liver again yielded no evidence of a tumor. Esophagoscopy showed the presence of varices grade 2. The liver at laparoscopy had the same appearance as it had in 1976. Histological examination of a biopsy specimen showed occasional dilated sinusoids and locally marked periportal and intralobular fibrosis. No regeneration nodules were found. The diagnosis was liver fibrosis. The patient's condition deteriorated gradually in the following years. She experienced increasing fatigue. Steatorrhea developed, and the patient lost weight. She needed increasing doses of cholestyramine and oral supplementation of vitamins A, D, and K. She was admitted for a 3rd time in February 1985. Esophagoscopy revealed varices grade 4. A CT scan of the liver showed no change. The patient successfully underwent an orthotopic liver transplantation in January 1987. The diagnosis of peliosis hepatis was well documented in this patient.
 ...
PMID:Generalized peliosis hepatis and cirrhosis after long-term use of oral contraceptives. 312 33

A syndrome of intrahepatic cholestasis leading to death in early childhood was studied in 16 Greenland Eskimo children. The pedigrees are compatible with autosomal recessive inheritance. Jaundice, bleeding, pruritus, malnutrition, steatorrhoea, osteodystrophy and dwarfism were typical clinical features. Eight had died between the ages of six weeks and three years due to bleeding or infections. Hyperbilirubinaemia, profound hypoprothrombinaemia, thrombocytosis and elevated alkaline phosphatase levels were evident. Serum calcium, phosphate and parathyroid hormone levels indicated a secondary hyperparathyroidism. Hepatic fibrosis developed with increasing age. Follow-up of the surviving patients was 4 to 30 months. The aetiology of the disease is unknown. The syndrome has some features in common with previously described patients with familial intrahepatic cholestasis. No specific treatment is available. Genetic counselling is essential.
 ...
PMID:Fatal familial cholestatic syndrome in Greenland Eskimo children. 356 58

Cryoglobulins were measured in 25 patients with PBC and, for comparison purposes, in 25 age- and sex-matched normal individuals as well as 25 patients with chronic active hepatitis (CAH). Cryoglobulins were present in all patients with PBC (median protein content 18 mg/l, range 8-233) and consisted predominantly of IgM, while none of the normal controls and only 20% of the patients with CAH had cryoglobulins. In PBC, a statistically significant correlation was found between cryoglobulin-IgM concentration and other immunological measurements, such as the serum IgM level (p = 0.003) and Clq binding (p less than 0.001). Cryoglobulin-IgM also correlated significantly with alkaline phosphatase (p = 0.002) and liver fibrosis (p = 0.013), but only in a larger group of patients with PBC. In a longitudinal study of patients with PBC, no changes in the cryoglobulin concentration were found following treatment with D-penicillamine alone or placebo, but the cryoglobulin-IgM level decreased significantly during low-dose combination therapy of D-penicillamine and prednisone (median 15,4 mg/l); this was accompanied by a statistically significant decrease in serum alkaline phosphatase. The relation between cryoglobulin-IgM, serum alkaline phosphatase and liver fibrosis is discussed with regard to the pathogenesis of PBC.
 ...
PMID:Cryoglobulins in primary biliary cirrhosis: prevalence and modulation by immunosuppressive therapy. 390 71


1 2 3 4 5 6 7 8 9 10 Next >>